No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALNY240719P230000
- 3.00
- +0.85+39.53%
15min DelayClose Jun 28 15:58 ET
3.00High2.00Low
2.00Open2.15Pre Close276 Volume523 Open Interest230.00Strike Price72.22KTurnover35.36%IV6.58%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry3.00Extrinsic Value100Contract SizeAmericanOptions Type-0.2317Delta0.0151Gamma85.26Leverage Ratio-0.1456Theta-0.0294Rho-19.75Eff Leverage0.1745Vega
Intraday
- 5D
- Daily
News
Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
US MOVERS&SHAKERS Jun 24-Jun 28, 2024
Alnylam Pharmaceuticals Is Maintained at Buy by UBS
Express News | Alnylam Pharmaceuticals Inc : UBS Raises Target Price to $288 From $253
UBS Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $288
Alnylam Pharmaceuticals(ALNY.US) Director Sells US$2.04 Million in Common Stock
Comments
2
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Substantial insider selling of Alnylam Pharmaceuticals shares over the last quarter, with no recorded purchases, may suggest insiders think shares are not cheap. Insider ownership suggests alignment with shareholder interests, but history of sales warrants caution before buying.
1
Read more